Neurona Therapeutics has announced the publication of preclinical data in Neuron reporting long-term engraftment and function of its human interneuron cell therapy candidate, NRTX-1001. According to the company, the study demonstrated that the transplanted cells survived, matured, and integrated into neural circuits for up to nine months in animal models of chronic focal epilepsy.
The company claims that these findings support the potential of NRTX-1001 as a regenerative approach to treat drug-resistant focal epilepsy, which affects hundreds of thousands of people in the United States alone. The therapy consists of human stem cell-derived medial ganglionic eminence (MGE)-type interneurons, designed to increase inhibitory signaling and reduce seizure activity.
Neurona said that in the preclinical study, the transplanted cells showed durable survival without overgrowth, migrated locally, and exhibited electrophysiological properties typical of mature interneurons. The company also noted that the treatment reduced seizure frequency in the animal models.
NRTX-1001 is currently being evaluated in an ongoing Phase I/II clinical trial (NCT05135091) in people with drug-resistant mesial temporal lobe epilepsy (MTLE). According to Neurona, initial clinical observations suggest the therapy is well tolerated, with some participants experiencing a reduction in seizure frequency.
The company claims that the published findings further validate the scientific foundation of NRTX-1001 and support its development as a one-time cell-based therapy for chronic focal epilepsy.
